# Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

> **NCT06148649** · PHASE2 · COMPLETED · sponsor: **Dongguan HEC Biopharmaceutical R&D Co., Ltd.** · enrollment: 234 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HEC88473, Placebo, Dulaglutide

## Key facts

- **NCT ID:** NCT06148649
- **Lead sponsor:** Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-10
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-04-23
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06148649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06148649, "Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06148649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*